Who Paid My Doc
Mark Williams
Nephrology Winter Park, FL Medical Doctor
NPI 1770558702 CMS profile 307054
3727 N Goldenrod Rd Ste 105, Winter Park, FL 32792
General payments
$1,493
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Mark Williams of Winter Park, FL is reported in the CMS Open Payments database as having received $1,493 across 54 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 57th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $440 | 15 | |
| 2022 | General | $293 | 15 | |
| 2021 | General | $332 | 11 | |
| 2020 | General | $360 | 9 | |
| 2019 | General | $67 | 4 |
Beside peers
- Mark Williams
- Nephrology median
- Middle half of Nephrology
- National median
In program year 2025, general payments to Mark Williams were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.
Show as a table
| Year | Mark Williams | Nephrology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $67 | $236 | $90–$588 | $163 |
| 2020 | $360 | $135 | $46–$364 | $114 |
| 2021 | $332 | $202 | $67–$551 | $132 |
| 2022 | $293 | $242 | $77–$695 | $149 |
| 2023 | $440 | $254 | $84–$766 | $160 |
| 2024 | $0 | $300 | $99–$852 | $164 |
| 2025 | $0 | $310 | $104–$880 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
208
Drug cost
$150,080
Branded share of claims
71.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 56 | $69,519 | |
| Farxiga Dapagliflozin Propanediol | Brand | 75 | $65,437 | |
| Kerendia Finerenone | Brand | 18 | $14,444 | |
| Calcitriol | Generic | 14 | $292 | |
| Losartan Potassium | Generic | 19 | $167 | |
| Doxazosin Mesylate | Generic | 14 | $146 | |
| Allopurinol | Generic | 12 | $76 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
54 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nephrology in Florida
Related records
Nephrology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Nephrology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.